158 related articles for article (PubMed ID: 33779078)
1. Multiplexed measurement of candidate blood protein biomarkers of heart failure.
Tonry C; McDonald K; Ledwidge M; Hernandez B; Glezeva N; Rooney C; Morrissey B; Pennington SR; Baugh JA; Watson CJ
ESC Heart Fail; 2021 Jun; 8(3):2248-2258. PubMed ID: 33779078
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure.
Watson CJ; Gupta SK; O'Connell E; Thum S; Glezeva N; Fendrich J; Gallagher J; Ledwidge M; Grote-Levi L; McDonald K; Thum T
Eur J Heart Fail; 2015 Apr; 17(4):405-15. PubMed ID: 25739750
[TBL] [Abstract][Full Text] [Related]
3. How B-Type Natriuretic Peptide (BNP) and Body Weight Changes Vary in Heart Failure With Preserved Ejection Fraction Compared With Reduced Ejection Fraction: Secondary Results of the HABIT (HF Assessment With BNP in the Home) Trial.
Maisel AS; Shah KS; Barnard D; Jaski B; Frivold G; Marais J; Azer M; Miyamoto MI; Lombardo D; Kelsay D; Iqbal N; Taub PR; Kupfer K; Lee E; Clopton P; Zile M; Greenberg B
J Card Fail; 2016 Apr; 22(4):283-93. PubMed ID: 26433086
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction.
Sinning C; Kempf T; Schwarzl M; Lanfermann S; Ojeda F; Schnabel RB; Zengin E; Wild PS; Lackner KJ; Munzel T; Blankenberg S; Wollert KC; Zeller T; Westermann D
Int J Cardiol; 2017 Jan; 227():272-277. PubMed ID: 27838133
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model.
Pufulete M; Maishman R; Dabner L; Mohiuddin S; Hollingworth W; Rogers CA; Higgins J; Dayer M; Macleod J; Purdy S; McDonagh T; Nightingale A; Williams R; Reeves BC
Health Technol Assess; 2017 Aug; 21(40):1-150. PubMed ID: 28774374
[TBL] [Abstract][Full Text] [Related]
6. Characterizing heart failure with preserved and reduced ejection fraction: An imaging and plasma biomarker approach.
Kanagala P; Arnold JR; Singh A; Chan DCS; Cheng ASH; Khan JN; Gulsin GS; Yang J; Zhao L; Gupta P; Squire IB; Ng LL; McCann GP
PLoS One; 2020; 15(4):e0232280. PubMed ID: 32349122
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Prognostic Significance of Plasma B-Type Natriuretic Peptide Level in Patients With Acute Heart Failure With Reduced, Mid-Range, and Preserved Ejection Fractions.
Hamatani Y; Nagai T; Shiraishi Y; Kohsaka S; Nakai M; Nishimura K; Kohno T; Nagatomo Y; Asaumi Y; Goda A; Mizuno A; Yasuda S; Ogawa H; Yoshikawa T; Anzai T;
Am J Cardiol; 2018 Mar; 121(6):731-738. PubMed ID: 29394996
[TBL] [Abstract][Full Text] [Related]
8. Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials.
Brunner-La Rocca HP; Eurlings L; Richards AM; Januzzi JL; Pfisterer ME; Dahlström U; Pinto YM; Karlström P; Erntell H; Berger R; Persson H; O'Connor CM; Moertl D; Gaggin HK; Frampton CM; Nicholls MG; Troughton RW
Eur J Heart Fail; 2015 Dec; 17(12):1252-61. PubMed ID: 26419999
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of brain natriuretic peptide in patients with heart failure and left ventricular ejection fraction higher than 60%: a sub-analysis of the J-MELODIC study.
Kitada S; Kikuchi S; Tsujino T; Masuyama T; Ohte N;
ESC Heart Fail; 2018 Feb; 5(1):36-45. PubMed ID: 28941144
[TBL] [Abstract][Full Text] [Related]
10. The utility of growth differentiation factor-15, galectin-3, and sST2 as biomarkers for the diagnosis of heart failure with preserved ejection fraction and compared to heart failure with reduced ejection fraction: a systematic review.
Rabkin SW; Tang JKK
Heart Fail Rev; 2021 Jul; 26(4):799-812. PubMed ID: 32472523
[TBL] [Abstract][Full Text] [Related]
11. BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study.
Khalid U; Wruck LM; Quibrera PM; Bozkurt B; Nambi V; Virani SS; Jneid H; Agarwal S; Chang PP; Loehr L; Basra SS; Rosamond W; Ballantyne CM; Deswal A
Int J Cardiol; 2017 Apr; 233():61-66. PubMed ID: 28185703
[TBL] [Abstract][Full Text] [Related]
12. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
[TBL] [Abstract][Full Text] [Related]
13. Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction.
de Boer RA; Nayor M; deFilippi CR; Enserro D; Bhambhani V; Kizer JR; Blaha MJ; Brouwers FP; Cushman M; Lima JAC; Bahrami H; van der Harst P; Wang TJ; Gansevoort RT; Fox CS; Gaggin HK; Kop WJ; Liu K; Vasan RS; Psaty BM; Lee DS; Hillege HL; Bartz TM; Benjamin EJ; Chan C; Allison M; Gardin JM; Januzzi JL; Shah SJ; Levy D; Herrington DM; Larson MG; van Gilst WH; Gottdiener JS; Bertoni AG; Ho JE
JAMA Cardiol; 2018 Mar; 3(3):215-224. PubMed ID: 29322198
[TBL] [Abstract][Full Text] [Related]
14. Catheter ablation for non-paroxysmal atrial fibrillation accompanied by heart failure with preserved ejection fraction: feasibility and benefits in functions and B-type natriuretic peptide.
Yamauchi R; Morishima I; Okumura K; Kanzaki Y; Morita Y; Takagi K; Nagai H; Watanabe N; Furui K; Yoshioka N; Miyazawa H; Shimojo K; Imaoka T; Sakamoto G; Murohara T
Europace; 2021 Aug; 23(8):1252-1261. PubMed ID: 33693617
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of B-Type Natriuretic Peptide for Predicting the Risk of Stroke in Patients With Heart Failure With Preserved Ejection Fraction.
Liu X; Abudukeremu A; Yu P; Cao Z; Sun R; Wu M; Chen Z; Ma J; Zhu W; Chen Y; Zhang Y; Wang J
J Am Heart Assoc; 2022 Aug; 11(15):e024302. PubMed ID: 35904188
[TBL] [Abstract][Full Text] [Related]
16. Biomarker profiling for risk of future heart failure (HFpEF) development.
Watson CJ; Gallagher J; Wilkinson M; Russell-Hallinan A; Tea I; James S; O'Reilly J; O'Connell E; Zhou S; Ledwidge M; McDonald K
J Transl Med; 2021 Feb; 19(1):61. PubMed ID: 33563287
[TBL] [Abstract][Full Text] [Related]
17. Sirt1 Activity in PBMCs as a Biomarker of Different Heart Failure Phenotypes.
Conti V; Corbi G; Polito MV; Ciccarelli M; Manzo V; Torsiello M; De Bellis E; D'Auria F; Vitulano G; Piscione F; Carrizzo A; Di Pietro P; Vecchione C; Ferrara N; Filippelli A
Biomolecules; 2020 Nov; 10(11):. PubMed ID: 33238655
[TBL] [Abstract][Full Text] [Related]
18. Differentiating heart failure phenotypes using sex-specific transcriptomic and proteomic biomarker panels.
Toma M; Mak GJ; Chen V; Hollander Z; Shannon CP; Lam KKY; Ng RT; Tebbutt SJ; Wilson-McManus JE; Ignaszewski A; Anderson T; Dyck JRB; Howlett J; Ezekowitz J; McManus BM; Oudit GY
ESC Heart Fail; 2017 Aug; 4(3):301-311. PubMed ID: 28772032
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of sST2 in patients with heart failure with reduced, mid-range and preserved ejection fraction.
Song Y; Li F; Xu Y; Liu Y; Wang Y; Han X; Fan Y; Cao J; Luo J; Sun A; Hu K; Zhou J; Ge J
Int J Cardiol; 2020 Apr; 304():95-100. PubMed ID: 32019693
[TBL] [Abstract][Full Text] [Related]
20. Combining Circulating MicroRNA and NT-proBNP to Detect and Categorize Heart Failure Subtypes.
Wong LL; Zou R; Zhou L; Lim JY; Phua DCY; Liu C; Chong JPC; Ng JYX; Liew OW; Chan SP; Chen YT; Chan MMY; Yeo PSD; Ng TP; Ling LH; Sim D; Leong KTG; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Lund M; Devlin G; Troughton R; Cameron VA; Doughty RN; Lam CSP; Too HP; Richards AM
J Am Coll Cardiol; 2019 Mar; 73(11):1300-1313. PubMed ID: 30898206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
